Journal of Comparative Effectiveness Research

Article	Citations
Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA	107
The economic cost of racial disparities in patients undergoing cardiac valve repair or replacement	88
Does off-hours endoscopic hemostasis affect outcomes of nonvariceal upper gastrointestinal bleeding?	43
Letter in reply	39
Corrigendum	38
Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost–effectiveness analysis	33
The views of teenagers with obesity, their caregivers, and doctors: a plain language summary of the ACTION Teens global survey	27
Journal of Comparative Effectiveness Research : 2022 year in review	23
Advanced or metastatic biliary tract cancer in Japan: a study using the Japan Medical Data Center payer claims database	22
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10	22
Real-world evidence on the effectiveness and safety of gliclazide MR 60 mg in Bangladeshi patients with Type II diabetes during fasting: a sub-analysis from the global DIA-RAMADAN study	22
A plain language summary of the long-term relugolix combination therapy study for uterine fibroids	21
Systematic literature review of evidence in amyloid light-chain amyloidosis	20
Meta-analysis of visual pretreatment for the prevention of emergence delirium in children undergoing ophthalmic surgery	19
Breast-conserving surgery versus mastectomy for older women with triple-negative breast cancer: population-based study	17
Phosphodiesterase type 5 inhibitors as treatment for erectile dysfunction: a webinar-based poll unveiling perceptions of healthcare professionals	17
Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making	17
Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer	17
Use of interrupted time-series analyses in evaluating health economic outcomes following implementation of multilayer water-tight wound closure in a primary total joint arthroplasty population	16
Healthcare resource utilization among nursing home residents with Parkinson's disease psychosis: an analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics	16
An observational cohort study of pelvic floor photobiomodulation for treatment of chronic pelvic pain	15
Patterns and association of vaccination among adults with a history of cancer in the USA: a population-based study	15
Screening for diminished ovarian reserve in Portugal: a cost-saving answer to shorten the fertility journey	15
The health-related quality of life of patients with a benign gynecological condition: a 2-year follow-up	14
Protocol for the implementation of a statewide mobile addiction program	14

Improved estimation of overall survival and progression-free survival for state transition modeling	14
Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost–effectiveness analysis	13
Corrigendum	12
Burden of illness for patients with primary biliary cholangitis: an observational study of clinical characteristics and healthcare resource utilization	12
Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas that can't be removed by surgery, and impact on how the condition affects caregivers: a plain language summary	12
The economic impact of stent retriever selection for acute ischemic stroke: a cost analysis of MASTRO I from the healthcare system perspective of the United States, Canada and eight European countries	12
Evaluation of reporting in time-driven activity-based costing studies on cardiovascular diseases: a scoping review	12
Access in all areas? A round up of developments in market access and health technology assessment: part 3	12
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 18	12
Corrigendum	12
Trends in adoption of knotless tissue control devices in robotic surgery	11
What works when: mapping patient and stakeholder engagement methods along the ten-step continuum framework	10
Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression	10
Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost–effectiveness analysis	10
US budget impact analysis of esketamine nasal spray in major depressive disorder with acute suicidal ideation/behavior	10
Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis	10
Comparative effectiveness research in COVID-19 using real-world data: methodological considerations	10
An impact evaluation of an education bundle for patients at risk of developing venous thromboembolism	9
Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma	9
Uricemia in the acute phase of myocardial infarction and its relation to long-term mortality risk	9
Postoperative outcomes and anesthesia type in total knee arthroplasty in patients with obstructive sleep apnea	9
The cost–effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark	9
Impact analysis of expanding anti-TNF therapy for Crohn’s disease	9
Effect of home-based exercise programs with e-devices on falls among community-dwelling older adults: a meta-analysis	9
Design and methods of a tailored approach for diabetes prevention in women with previous gestational diabetes	9
Effects of 12-week Pilates training program on cardiac autonomic modulation: a randomized controlled clinical trial	8
Health technology assessments and real-world evidence: tell us what you want, what you really, really want	8
Cost–effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes	8
Engaging veterans in the research process: a practical guide	8
Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy	7
Reducing length of antibiotics for children with ear infections: protocol for a cluster-randomized trial in the USA	7
Cost–effectiveness of pembrolizumab for second-line treatment of esophageal squamous cell carcinoma patients with a combined positive score of 10 or more	7
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 12	7
Comparative economic outcomes in patients with focal seizures initiating eslicarbazepine acetate versus brivaracetam in the long-term care setting in the USA	7
A clinical decision support tool for metabolic dysfunction-associated steatohepatitis in real-world clinical settings: a mixed-method implementation research study protocol	7
Corrigendum	7
Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma	7
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers	7
Patterns of emergency department visits preceding colorectal cancer diagnosis: a population-based study	7
Acute effects of resistance exercise with blood flow restriction on cardiovascular response: a meta-analysis	6
Novel and existing flexible survival methods for network meta-analyses	6
Efficacy classification of modern therapies in multiple sclerosis	6
Redesign of radiotherapy for prostate cancer: a proposal for universal healthcare systems	6
Cost–effectiveness of concurrent radiation with cetuximab or chemotherapy in older patients with oropharyngeal cancer	6
Regional differences in the utilization and outcomes of cerebral embolic protection during transcatheter aortic valve replacement: an analysis of the National Inpatient Sample from 2017 through 2019	6
A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications	6
Navigating adalimumab biosimilars: an expert opinion	6
RWE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 16	6
Are treatment effects consistent with hypothesized mechanisms of action proposed for postoperative delirium interventions? Reanalysis of systematic reviews	6
Cost–effectiveness analysis of a resource-intensive approach versus minimally invasive strategy for high-risk transcatheter aortic valve replacement patients	6

Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case–control design	6
Early mobilization in enhanced recovery after surgery pathways: current evidence and recent advancements	6
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy	6
The impact of a patient advisory board on a clinical comparative effectiveness trial: a comparison of patient and researcher perspectives	6
Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary	6
Distinguishing cardiac catheter ablation energy modalities by applying natural language processing to electronic health records	6
Current practice of stakeholder engagement: researchers’ experiences in North America, DACH countries and China	6
Discharges against medical advice and 30-day healthcare costs: an analysis of commercially insured adults	5
Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary	5
Cost–effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China	5
Institute for Clinical and Economic Review – Peterson Health Technology Institute value assessment framework for digital health technologies	5
Comparing prospectively assigned trial and real-world lung cancer patients	5
Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies	5
Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers	5
Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?	5
Cost–effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China	5
Missing data methods for intensive care unit SOFA scores in electronic health records studies: results from a Monte Carlo simulation	5
An investigation to choose the proper therapy technique in the management of autism spectrum disorder	5
Treatment goals for rheumatoid arthritis: patient engagement and goal collection	5
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 7	5
Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer	4
Assessing the change in disease severity based on depressive symptoms in real-world psoriasis patients	4
Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study	4
Corrigendum	4
Visualizing the randomized sham-controlled trial in orthopedic research: proposed steps to conducting a total knee arthroplasty randomized controlled trial	4
White bagging, brown bagging and site of service policies: best practices in addressing provider markup in the commercial insurance market	4
A value-based budget impact model for dronedarone compared with other rhythm control strategies	4
A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer	4
Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy	4
Access in all areas? a round up of developments in market access and health technology assessment: part 4	4
An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD	4
Polymer-based drug-eluting stent treatment extends the time to reintervention for patients with symptomatic femoropopliteal artery disease: clinical evidence and potential economic value	4
Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma	4
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 8	4
Real-world treatment, clinical outcomes and healthcare resource utilization among persons with hemophilia A by age	4
A real world cost-minimization analysis comparing the use of different endoscopic staplers in video-assisted thoracic surgery lobectomy procedures	4
Gastrointestinal adverse effects associated with the use of intravenous oliceridine compared with intravenous hydromorphone or fentanyl in acute pain management utilizing adjusted indirect treatment c	4
Expanding the learning health system model to be health literate	4
The impact of lower limb chronic venous disease on quality of life: patient and physician perspectives	4
An economic evaluation of teledermatology care delivery for chronic skin diseases	4
Impact of clinical research coordinators on research output in orthopedic surgery	4
A clinical systematic literature review of treatments among patients with advanced and/or metastatic human epidermal growth factor receptor 2 positive breast cancer	4
Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis	4
Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome	4
Use of ibuprofen for the closure of patent ductus arteriosus in preterm infants: a systematic review of meta-analyses	4
Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis	4
MASTRO I: Meta-Analysis and Systematic Review of thrombectomy stent retriever outcomes: comparing functional, safety and recanalization outcomes between EmboTrap, Solitaire and Trevo in acute ischemic	4
Promoting community stakeholder engagement in research on treatment for pregnant women with opioid use disorder	4
Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia	4
Cost standard set program: moving forward to standardization of cost assessment based on clinical condition	4
Matching-adjusted indirect comparison via a polynomial-based non-linear optimization method	4
Development of healthcare and social care services for the elderly population	3
Economic burden of lives lost due to COVID-19 in New York State	3
Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy	3
Restoring rotational stability following anterior cruciate ligament surgery: single-bundle reconstruction combined with lateral extra-articular tenodesis versus double-bundle reconstruction	3
Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use	3
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 13	3
Prognostic and predictive value of microsatellite instability status among patients with colorectal cancer	3
Learning from the past to advance tomorrow’s real-world evidence: what demonstration projects have to teach us	3
Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries	3
Use of transportability methods for real-world evidence generation: a review of current applications	3
Costs and outcomes of mobile cardiac outpatient telemetry monitoring post-transcatheter aortic valve replacement	3
Cost–utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma	3
The next generation of rare disease drug policy: ensuring both innovation and affordability	3
Celebrating 10 years of the Journal of Comparative Effectiveness Research	3
Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer?	3
Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data	3
Access in all areas? A round up of developments in market access and HTA: part 5	3
Advantages of robotic arm-assisted total hip arthroplasty: a 90-day episode-of-care clinical utility and cost analysis	3
Navigating the unknown: how to best ‘reflect’ standard of care in indications without a dedicated treatment pathway in health technology assessment submissions	3
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting	3
Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant	3
Evaluation of hypercholesterolemia management in at-risk patients by cardiologists in France: a case vignette-based study	3
Implementation science: accelerating the pharma pipeline to its full potential	3
Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective	3
PEG hydrogel sealant versus fibrin glue in posterior fossa surgery: an economic comparison across five European countries	3
A prospective, randomized, controlled, crossover study comparing three multilayered foam dressings for the management of chronic wounds	3
Journal of Comparative Effectiveness Research welcoming the submission of study design protocols to foster transparency and trust in real-world evidence	3
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US	3
Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain	3

Perceptions of indirect treatment comparisons as an evidence base in oncology decision-making: results of an international survey of health technology assessment and payer decision-makers	3
Outcomes of patients with nonmetastatic gastric adenocarcinoma according to perioperative treatment strategy: a real-world, population-based study	3
Real-world economic and clinical outcomes associated with current hemostatic matrix use in spinal surgery	3
The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA	3
Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis	3
The economic impact associated with stent retriever selection for the treatment of acute ischemic stroke: a cost–effectiveness analysis of MASTRO I data from a Chinese healthcare system perspective	3
Access to medicines in the Brazilian Unified Health System’s primary health care: assessment of a public policy	3
Corrigendum	3
Impact of surgical complications on hospital costs and revenues: retrospective database study of Medicare claims	3
Clinical and utilization outcomes associated with tumor mutational burden in a real-world pan-tumor population	3
Structural hemodynamic valve deterioration durability of RESILIA-tissue versus contemporary aortic bioprostheses	3
Using multiple imputation of real-world data to estimate clinical remission in pediatric inflammatory bowel disease	3
Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban	3
Mapping methods gaps between EU joint clinical assessments and local health technology assessment decision-making: an environmental scan of guidance in select EU markets and harmonization challenges	3
Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer	3
In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database	3
Impact of telehealth on health care resource utilization during the COVID-19 pandemic	3
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib	3
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity	3
Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis	3
Letter in reply	3
Effect of clinical Pilates training on balance and postural control in patients with Parkinson’s disease: a randomized controlled trial	3
A real-world comparison of the clinical and economic utility of OVA1 and CA125 in assessing ovarian tumor malignancy risk	3
Generalized cost–effectiveness analysis: charting a path forward for measuring the societal value of medical technologies	3
Why is the market design for innovative pharmaceuticals not well understood?	3
Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis	3
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 17	3
Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study	2
Robotic-assisted total hip arthroplasty: an economic analysis	2
Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points	2
Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study	2
Outcome domains and measures for pain in psoriasis used in registered trials: analysis of studies on ClinicalTrials.gov	2
Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis in induction and maintenance: systematic literature review and Bayesian network meta-analysis	2
Economic impact of reduced postoperative visits after inflatable penile prosthesis implantation	2
Real-world evidence: state-of-the-art and future perspectives	2
Economic burden of complicated ureteral stent removal in patients with kidney stone disease in the USA	2
Streamlined versus traditional consent for low-risk comparative effectiveness trials: a randomized experimental study to measure patients' and public attitudes	2
Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status	2
Using real-world evidence in healthcare from Western to Central and Eastern Europe: a review of existing barriers	2
Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer	2
Effectiveness of bisoprolol versus other β-blockers and other antihypertensive classes: a cohort study in the Clinical Practice Research Datalink	2
A US national update of health condition prevalence among privately-insured autistic adults	2
The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies	2
True cost of surgical aortic valve replacement and implications for price setting and diagnosis-related groups: evidence from a tertiary hospital in Eastern China	2
Healthcare and economic burden of anticholinergic use in adults with overactive bladder: a systematic literature review	2
Effects of cardiovascular single pill combinations compared with identical multi-pill therapies on healthcare cost and utilization in Germany	2
Healthcare utilization and costs following molecular diagnostic testing among patients with vaginitis	2
Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review	2
Variant analysis of SARS-CoV-2 strains with phylogenetic analysis and the Coronavirus Antiviral and Resistance Database	2
DAPA-RWE: a retrospective multicenter study comparing dapagliflozin and sitagliptin in patients with Type 2 diabetes treated under routine clinical practice in Spain	2
Application of quantitative bias analysis for unmeasured confounding in cost–effectiveness modelling	2
Vaginal laser therapy for gynecologic conditions: re-examining the controversy and where do we go from here	2
Ravulizumab in adults and children with atypical hemolytic uremic syndrome: a plain language summary of three studies	2
Improving access to gene therapies: a holistic view of current challenges and future policy solutions in the United States	2
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma	2
Steroid switching in dystrophinopathy treatment: a US chart review of patient characteristics and clinical outcomes	2
Clinical assessment of the potential use of a novel single-dose prefilled injection device for the administration of Acthar Gel in children: a narrative review	2
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15	2
Lessons on the use of real-world data in medical device research: findings from the National Evaluation System for Health Technology Test-Cases	2
COVID-19 complications in males and females: recent developments	2
A review of 25 years of National Institute of Health and Care Excellence decision making	2
EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?	2
QDOT MICRO™ versus THERMOCOOL ® SMARTTOUCH™ and THERMOCOOL SMARTTOUCH ® Surround Flow in radiofrequency ablation of paroxysmal atr	2
For what it's worth: the complex area of medicine value assessment	2
Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis	2
Cost–effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China	2
Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain	1
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 11	1
Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson’s disease: a systematic review and meta-analysis	1
The real-world impact of National Institute for Health and Care Excellence's real-world evidence framework	1
First in class, best in class or a wild card: who will dominate the anti-obesity medication market?	1
Cost–effectiveness analysis of Avance ® allograft for the treatment of peripheral nerve injuries in the USA	1
Impact of comparative effectiveness research on Medicare coverage of direct oral anticoagulants	1
The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health	1
A real-world analysis of antidepressant medications in US veterans aged 60 years and older: a comparative analysis	1
Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China	1
Willingness to pay for a hypothetical malaria vaccine in Brazil: a cross-sectional study and the implications	1
Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison	1
Managing the challenges of paying for gene therapy: strategies for market action and policy reform in the United States	1
Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations	1
Cost–utility analysis of single nucleotide polymorphism panel-based machine learning algorithm to predict risk of opioid use disorder	1
Validity of comorbidity adjustment scores in estimating in-hospital mortality in individual subgroups of race/ethnicity	1
Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus	1
Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review	1
The burden of Alagille syndrome: uncovering the potential of emerging therapeutics – a comprehensive systematic literature review	1
Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients	1
Consumer willingness to pay for a hypothetical Chagas disease vaccine in Brazil: a cross-sectional study and the implications	1
Impact of clinical pathways on treatment patterns and outcomes for patients with non-small-cell lung cancer: real-world evidence from a community oncology practice	1
Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A	1
Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims	1
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 4	1
Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations	1
Assessing the performance of physician's prescribing preference as an instrumental variable in comparative effectiveness research with moderate and small sample sizes: a simulation study	1
Evaluating the robustness of an AI pathfinder application on eligibility criteria in multiple myeloma trials using real-world data and historical trials	1
Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizumab	1